RxDoctor Payments Data

Kurt Hepworth

Optometrist · South Jordan, UTNPI 1457531428

Payments from drug & device makers

$1,156in general payments, 2019–2025

Across 39 payments — averaging $29.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$501
  • AbbVie$133
  • Shire North American Group Inc$102
  • Biotissue Holdings Inc.$65
  • Carl Zeiss Meditec, Inc.$60
  • Novartis$58
  • plus $236 from 9 others

What the payments were for

  • Food & beverage$1,11797%
  • Gifts$393%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,156 in reported general payments places this provider in the 60th percentile of 423 optometrist providers in Utah.

See all optometrist providers in Utah

Medicare billing

Part B allowed, 2024
$95,787
Medicare patients
628
Services billed
1,109

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine67$79,702
Prednisolone Acetate247$8,292
LumiganBimatoprost15$6,967
Cyclosporine15$4,927
Ketorolac Tromethamine221$4,184
Ciprofloxacin Hcl202$2,742
Latanoprost66$617
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha45$550
Timolol Maleate50$270
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat24$168
Brimonidine Tartrate16$95

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$133$86,66982 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 423 optometrist providers in Utah.

Other optometrist in South Jordan

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →